VARIBAR THIN HONEY Drug Patent Profile

When do Varibar Thin Honey patents expire, and what generic alternatives are available?

Varibar Thin Honey is a drug marketed by Bracco and is included in one NDA.

The generic ingredient in VARIBAR THIN HONEY is barium sulfate. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the barium sulfate profile page.

Summary for VARIBAR THIN HONEY

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	104
Clinical Trials:	1
What excipients (inactive ingredients) are in VARIBAR THIN HONEY?	VARIBAR THIN HONEY excipients list
DailyMed Link:	VARIBAR THIN HONEY at DailyMed

Recent Clinical Trials for VARIBAR THIN HONEY

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Northwell Health	Phase 2

See all VARIBAR THIN HONEY clinical trials

Pharmacology for VARIBAR THIN HONEY

Drug Class	Radiographic Contrast Agent
Mechanism of Action	X-Ray Contrast Activity

US Patents and Regulatory Information for VARIBAR THIN HONEY

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bracco	VARIBAR THIN HONEY	barium sulfate	SUSPENSION;ORAL	208143-006	Jan 23, 2018		RX	Yes	Yes

VARIBAR Thin Honey Market Dynamics, Patent Position, and Financial Trajectory

Last updated: July 31, 2026

VARIBAR Thin Honey is a prescription barium sulfate oral suspension marketed by Bracco Diagnostics for videofluoroscopic evaluation of oropharyngeal swallowing function in patients with dysphagia. The product received FDA approval in 2017 under NDA 209684. Its market is specialized and institutionally purchased, with demand tied to hospitals, speech-language pathology services, radiology departments, stroke care, and long-term-care networks.[1]

Bracco does not publicly report VARIBAR Thin Honey revenue as a standalone product. The available public record supports a market assessment based on FDA status, product positioning, healthcare utilization, competitive substitutes, and Bracco’s broader diagnostic-imaging business rather than a verified product-level sales forecast.

What is VARIBAR Thin Honey and who uses it?

VARIBAR Thin Honey is a 40% weight/volume barium sulfate suspension used during modified barium swallow studies, also called videofluoroscopic swallow studies. The product has a honey-like viscosity designed to evaluate swallowing under a standardized consistency.[1]

The primary users are:

• Hospitals and outpatient radiology centers
• Speech-language pathologists
• Ear, nose and throat specialists
• Neurology and stroke-care programs
• Long-term-care and rehabilitation facilities
• Pediatric and geriatric dysphagia programs

Barium sulfate is radiopaque and passes through the gastrointestinal tract without systemic absorption. VARIBAR Thin Honey is therefore a diagnostic contrast agent rather than a therapeutic drug.

Which patients generate demand for VARIBAR Thin Honey?

Demand is linked to conditions that impair swallowing, including:

• Stroke
• Parkinson’s disease
• Amyotrophic lateral sclerosis
• Multiple sclerosis
• Dementia
• Head and neck cancer
• Traumatic brain injury
• Developmental and neuromuscular disorders
• Age-related swallowing impairment

The American Speech-Language-Hearing Association identifies videofluoroscopic swallowing studies as an established diagnostic approach for assessing oropharyngeal swallowing physiology and aspiration risk.[2]

What is the FDA status of VARIBAR Thin Honey?

VARIBAR Thin Honey was approved by the FDA on September 19, 2017, under NDA 209684.[1] It is an approved prescription oral suspension and is not a biologic.

Regulatory item	Status
Product	VARIBAR Thin Honey
Active ingredient	Barium sulfate
Dosage form	Oral suspension
Strength	40% w/v
Route	Oral
FDA application	NDA 209684
Sponsor	Bracco Diagnostics Inc.
Approval date	September 19, 2017
Therapeutic use	Diagnostic imaging of the oropharyngeal swallowing mechanism
Product type	Small-molecule diagnostic contrast agent
Biosimilar pathway	Not applicable

The FDA approval was for a specific viscosity and diagnostic use. That positioning differentiates VARIBAR Thin Honey from general-purpose barium products used for esophageal, gastric, or intestinal imaging.

What patents protect VARIBAR Thin Honey?

The publicly visible commercial protection for VARIBAR Thin Honey is primarily regulatory and formulation-based rather than dependent on a high-value compound patent. Barium sulfate is an established inorganic contrast agent and is not a newly invented active pharmaceutical ingredient.

The relevant protection categories are:

1. Formulation design. A commercially standardized suspension with a defined barium concentration, viscosity, palatability profile, and physical stability.
2. Diagnostic-use positioning. Use in swallowing examinations at a defined consistency.
3. Manufacturing know-how. Particle-size control, dispersion, suspension stability, filling, packaging, and quality testing.
4. Brand and trade dress. VARIBAR is a commercial brand family used across multiple viscosity grades.

The FDA Orange Book should be reviewed for the current patent and exclusivity entries associated with NDA 209684. Public product-level materials do not establish a long-duration active-ingredient patent estate comparable with patented small-molecule therapeutics. The commercial barrier is more likely to involve manufacturing consistency, hospital protocol adoption, contracting, and regulatory execution.

When did VARIBAR Thin Honey lose exclusivity?

Any three-year FDA exclusivity associated with approval of a new dosage form, formulation, or indication would have expired no later than 2020, assuming it was granted from the September 2017 approval date. The FDA’s approval record and current Orange Book entries control the definitive exclusivity and patent position.[1,3]

VARIBAR Thin Honey does not have biologic exclusivity. Biosimilar approval rules therefore do not apply. A competing product would generally be evaluated under the drug approval framework, but a direct generic pathway may be commercially unattractive because the product’s value depends on viscosity, suspension performance, clinical workflow, and institutional acceptance.

What is the Orange Book status of VARIBAR Thin Honey?

VARIBAR Thin Honey is an NDA-approved prescription product listed in FDA drug databases. The Orange Book is the relevant source for determining whether Bracco has listed patents or exclusivity for NDA 209684.[3]

An absence of a meaningful current patent barrier would not eliminate commercial protection. Hospitals often purchase contrast agents through formularies, group purchasing organizations, distributor contracts, and radiology supply agreements. Those channels can delay substitution even when formal patent protection is limited.

Are there Paragraph IV challenges or patent litigation involving VARIBAR Thin Honey?

No widely reported Paragraph IV dispute or major federal patent litigation involving VARIBAR Thin Honey is established in the principal public FDA and company materials reviewed for this market assessment.

The limited litigation profile is consistent with the product’s characteristics:

• The active ingredient is old and inexpensive to manufacture in principle.
• The indication is narrow.
• Clinical use is protocol-driven.
• Product demand is concentrated in institutional settings.
• The addressable market is substantially smaller than the market for mass-prescribed medicines.

A future challenger would more likely compete through a separate barium formulation, an alternative viscosity product, or a broader contrast-agent portfolio than through a high-profile patent invalidity campaign.

How large is the VARIBAR Thin Honey market?

The market is niche and difficult to isolate in public datasets. Bracco does not disclose VARIBAR Thin Honey revenue separately, and hospital purchases may be bundled with other Bracco contrast agents.

Market demand depends on procedure volume rather than daily patient prescriptions. Important drivers include:

• Growth in dysphagia screening after stroke
• Expansion of outpatient imaging
• Aging populations
• Increased diagnosis of neurodegenerative disease
• Greater attention to aspiration-related complications
• Use of standardized consistencies in swallowing protocols
• Recovery of elective diagnostic procedures after pandemic disruptions

Revenue is likely generated through recurring institutional consumption rather than high per-patient chronic-treatment revenue. A single facility can purchase several VARIBAR viscosity grades, but utilization can fluctuate with staffing, radiology capacity, referral patterns, and local clinical protocols.

What limits market growth?

The main constraints are:

• A narrow diagnostic indication
• Substitution by other barium preparations
• Availability of thickened liquids and food-based test materials
• Variation in modified barium swallow protocols
• Budget pressure on hospital radiology departments
• Limited product differentiation from a payer perspective
• Dependence on speech-language pathology capacity

The product does not benefit from the prescription-refill dynamics of chronic medicines. Its demand is procedural and episodic.

How does VARIBAR Thin Honey compare with competing products?

VARIBAR Thin Honey competes in a broader contrast-agent and swallowing-assessment market rather than against one identical branded product.

Competitive category	Relevance to VARIBAR Thin Honey	Commercial effect
Other VARIBAR viscosities	Direct internal substitute or companion product	Supports portfolio contracting and protocol matching
General barium suspensions	May be used in gastrointestinal imaging or adapted in some settings	Creates price pressure where viscosity specifications are less strict
Alternative commercial barium products	Compete for radiology department budgets	Can reduce switching costs for institutions
Thickened liquids or food-based materials	Used in some swallowing assessments	May substitute in selected protocols
Fiberoptic endoscopic evaluation of swallowing	Competing diagnostic procedure	Can reduce videofluoroscopic study volume in certain settings
Non-barium imaging approaches	Limited direct substitution	Usually less relevant for dynamic swallow assessment

The strongest product advantage is workflow specificity. VARIBAR Thin Honey is ready-made and standardized, while improvised alternatives may create variability in viscosity, radiopacity, preparation, and documentation.

How strong is the VARIBAR Thin Honey patent estate?

The patent estate appears commercially modest compared with branded therapeutic drugs. The defensible elements are more likely to be:

• Formulation and suspension specifications
• Manufacturing process controls
• Brand recognition
• Hospital purchasing relationships
• Clinical familiarity
• Portfolio economics across VARIBAR products

The formulation barrier can still matter. A competitor must produce a suspension that remains uniform, has acceptable taste and texture, provides adequate radiopacity, and performs consistently during fluoroscopy. Regulatory approval also requires product quality data and labeling that support the intended use.

This type of protection is weaker against a technically capable manufacturer than a composition-of-matter patent, but it can support durable share in a narrow institutional market.

What is the financial trajectory of VARIBAR Thin Honey?

Product-level revenue, gross margin, unit volume, and operating profit are not publicly disclosed. Bracco is privately held, and its public communications emphasize company-level diagnostics and imaging operations rather than individual VARIBAR SKUs.[4]

The likely financial trajectory has four phases:

2017 to 2020: Launch and regulatory adoption

The initial period involved formulary placement, radiology education, and adoption by institutions performing standardized modified barium swallow studies. Revenue growth would have depended on converting sites from general barium products or locally prepared consistencies.

2020 to 2022: Procedure disruption

The COVID-19 period disrupted elective and outpatient procedures, including diagnostic imaging and swallowing evaluations. Hospital staffing constraints and reduced procedure volumes likely affected demand across contrast-agent categories.

2022 onward: Utilization recovery

Recovery depends on hospital procedure volumes, stroke-care pathways, outpatient imaging, and rehabilitation activity. The product benefits from recurring use where institutions standardize the VARIBAR family across thin, nectar, honey, pudding, and regular consistencies.

Mature phase: Stable niche revenue

The likely mature profile is stable, low-growth revenue with limited price elasticity in sites that value standardized preparation. Growth is more likely to come from wider institutional adoption and increased dysphagia testing than from premium pricing.

What generic launch risks exist for VARIBAR Thin Honey?

A generic or alternative entrant could reduce price and increase contracting pressure. The most credible scenarios are:

1. Direct equivalent launch. A competitor obtains approval for a closely matching barium suspension and targets hospital formularies.
2. Portfolio competition. A contrast-agent manufacturer offers several viscosity grades under one institutional contract.
3. Non-branded substitution. Facilities use other barium products or locally prepared consistencies where protocols permit.
4. Procedure substitution. Greater use of fiberoptic endoscopic swallowing evaluation reduces demand for fluoroscopic studies.

The near-term commercial risk is more likely to be gradual price erosion than abrupt displacement. Institutional conversion requires validation, clinician acceptance, supply reliability, and contracting changes.

What licensing deals affect VARIBAR Thin Honey?

No major publicly disclosed licensing transaction specifically tied to VARIBAR Thin Honey is established in the principal public sources. Bracco’s control of the VARIBAR brand and its diagnostic-contrast portfolio gives the company the primary commercial position.

Potential transaction value would be higher for a buyer seeking:

• Access to hospital radiology accounts
• A complete barium product portfolio
• Manufacturing and quality systems
• Cross-selling opportunities with CT, MRI, and gastrointestinal contrast agents

A standalone acquisition of VARIBAR Thin Honey would likely have limited strategic value unless bundled with related diagnostic products.

Key Takeaways

• VARIBAR Thin Honey is a niche, FDA-approved barium sulfate suspension for modified barium swallow studies.
• Bracco Diagnostics received FDA approval on September 19, 2017, under NDA 209684.
• Public sources do not disclose standalone revenue or profit for the product.
• The product has no biologic or biosimilar exposure.
• Its commercial protection relies more on formulation execution, brand, workflow integration, and institutional contracts than on a valuable new active-ingredient patent.
• Any three-year FDA exclusivity associated with approval would have expired by 2020, subject to the FDA’s official Orange Book record.
• No major publicly reported Paragraph IV challenge or patent litigation is established.
• Market growth depends on dysphagia diagnosis, stroke and neurological care, aging demographics, and modified barium swallow procedure volumes.
• Generic risk is gradual and procurement-driven, with the greatest exposure from competing standardized barium formulations and broader contrast-agent portfolios.

FAQs about VARIBAR Thin Honey

Is VARIBAR Thin Honey a therapeutic drug?

No. It is a diagnostic contrast agent containing barium sulfate for radiographic assessment of swallowing.

Who manufactures VARIBAR Thin Honey?

Bracco Diagnostics Inc. markets VARIBAR Thin Honey in the United States.

Does VARIBAR Thin Honey have biosimilar competition?

No. Biosimilar rules apply to biologics, while VARIBAR Thin Honey is a nonbiologic barium sulfate suspension.

Can hospitals substitute another barium product for VARIBAR Thin Honey?

Potentially, depending on the product’s viscosity, radiopacity, labeling, institutional protocol, and regulatory status. Substitution is a clinical and procurement decision rather than an automatic generic interchange.

Is VARIBAR Thin Honey revenue publicly reported?

No standalone product revenue is publicly reported. Bracco’s public disclosures do not provide a separate sales line for VARIBAR Thin Honey.

References

1. U.S. Food and Drug Administration. (2017). VARIBAR Thin Honey: NDA 209684 approval information and prescribing information. https://www.accessdata.fda.gov
2. American Speech-Language-Hearing Association. (n.d.). Adult dysphagia: Assessment and treatment. https://www.asha.org/practice-portal/clinical-topics/adult-dysphagia/
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.accessdata.fda.gov/scripts/cder/ob/
4. Bracco. (n.d.). Bracco Diagnostics and contrast media portfolio. https://www.bracco.com